Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 7/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.34 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.34 |
| ▸ | TEAD2 | Q15562 | 2/20 | 0.34 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496874 | 0.89 | TAS2R14 (0.37) | TAS2R14ARSCN9ATRPA1 | |
| SCHEMBL495554 | 0.87 | TAS2R14 (0.40) | TAS2R14ARTRPA1 | |
| SCHEMBL30294636 | 0.84 | TAS1R3 (0.44) | TAS2R14ARTRPA1TEAD1TEAD4 | |
| SCHEMBL22833433 | 0.84 | TAS1R3 (0.44) | TAS2R14ARTRPA1TEAD1TEAD4 | |
| SCHEMBL22853405 | 0.84 | TAS1R3 (0.44) | TAS2R14ARTRPA1TEAD1TEAD4 | |
| SCHEMBL496028 | 0.81 | TAS2R14 (0.42) | TAS2R14ARTRPA1 | |
| SCHEMBL496533 | 0.81 | TAS2R14 (0.42) | TAS2R14ARTRPA1 | |
| SCHEMBL496239 | 0.81 | TAS2R14 (0.40) | TAS2R14AR | |
| SCHEMBL495472 | 0.78 | KDM4E (0.44) | TAS2R14PTK2 | |
| SCHEMBL22853016 | 0.73 | TAS2R14 (0.39) | TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | TAS2R14 607/4885AR 398/4885PTK2 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.